COMPANY

Products and Pipeline

We are an elite biotechnology company that is setting the new standard in healthcare, focused on innovative aesthetic and therapeutic offerings, as well as financial technology services for aesthetic practices.

COMPANY

Products and Piepine

We are an elite biotechnology company that is setting the new standard in healthcare, focused on innovative aesthetic and therapeutic offerings, as well as financial technology services for aesthetic practices.

MUSKRAT

DaxibotulinumtoxinA for Injection was approved for the treatment of moderate to severe frown lines (glabellar lines) in adults. Revance is also evaluating DaxibotulinumtoxinA for Injection for additional use in aesthetic medicine including the full upper face, forehead lines and crow’s feet and in therapeutic indications, including cervical dystonia and upper limb spasticity.

Revance Aesthetics is building the prestige market for aesthetics comprised of expertly created products and services that are available exclusively in select practices who produce exceptional consumer experiences and outcomes.

Our investigational neuromodulator product, DaxibotulinumtoxinA for Injection, is aiming to establish a new, premium, long-lasting neuromodulator category. DaxibotulinumtoxinA for Injection is an investigational agent that has not been approved by the FDA and is currently under regulatory review.

RHA® – resilient hyaluronic acid – is the latest advancement in HA filler science. The RHA® Collection of fillers are the first and only HA fillers FDA-approved for dynamic wrinkles and folds.

Unique financial technology platform designed to transform existing payment processing ecosystems and improve both aesthetic economics and patient experiences.

Revance’s therapeutic pipeline seeks to bring innovation to multiple indications in muscle movement and pain disorders. 

INDICATION
DaxibotulinumtoxinA for Injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.

WARNING: DISTANT SPREAD OF TOXIN EFFECT
The effects of DaxibotulinumtoxinA for Injection and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DaxibotulinumtoxinA for Injection is not approved for the treatment of spasticity or any conditions other than glabellar lines.

IMPORTANT SAFETY INFORMATION

Contraindications
DaxibotulinumtoxinA for Injection contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).

Warnings and Precautions
Please refer to Boxed Warning for Distant Spread of Toxin Effect.

The potency Units of DaxibotulinumtoxinA for Injection are not interchangeable with other preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.

Adverse Reactions
The most commonly observed adverse reactions (≥1%) were headache (6%), eyelid ptosis (2%) and facial paresis (1%).

Drug Interactions
Co-administration of DaxibotulinumtoxinA for Injection and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DaxibotulinumtoxinA for Injection may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DaxibotulinumtoxinA for Injection is unknown.

Use in Specific Populations
DaxibotulinumtoxinA for Injection is not recommended for use in children or pregnant women.

Please see DaxibotulinumtoxinA for Injection full Prescribing Information, including Boxed Warning and Medication Guide.